HomeAbout GlaucomaYour TreatmentSafety InformationTalking to Your DoctorSave Now
 About Glaucoma - Patient Resources

Patient Resources

The following are recommended resources with additional information for glaucoma patients:

  • Children's Glaucoma Foundation (childrensglaucoma.com)
  • The Glaucoma Foundation (glaucomafoundation.org)
  • Glaucoma Research Foundation (glaucoma.org)
  • GRF's Gleams Newsletter (glaucoma.org/news)
  • Glaucoma Service Foundation to Prevent Blindness
    at Wills Eye Hospital (willsglaucoma.org)
  • International Glaucoma Association (glaucoma-association.com)
  • New York Glaucoma Research Institute (glaucoma.net)

Allergan accepts no responsibility for the content of these sites. Allergan does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Allergan.

Indication: COMBIGAN® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is approved for reducing elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. COMBIGAN® lowers IOP slightly less than taking both brimonidine tartrate three times a day and timolol maleate two times a day.

Contraindications: COMBIGAN® ophthalmic solution should not be used by patients who have or ever had a reactive airway disease including bronchial asthma, chronic bronchitis, emphysema, slow heartbeat, impaired conduction of the heart, heart failure, or impaired pumping of the heart. COMBIGAN® should not be used in patients aged 2 years and younger, or by patients with hypersensitivity to any ingredient in this product.

See more below.